Get the Stockscreener App
3.14
0.63%
-0.02
After Hours:
3.12
-0.02
-0.64%
23 Andme Holding Co stock is traded at $3.14, with a volume of 339.36K.
It is down -0.63% in the last 24 hours and down -32.76% over the past month.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
See More
Previous Close:
$3.16
Open:
$3.17
24h Volume:
339.36K
Relative Volume:
1.19
Market Cap:
$82.53M
Revenue:
$247.99M
Net Income/Loss:
$-521.97M
P/E Ratio:
-4.3611
EPS:
-0.72
Net Cash Flow:
$-194.28M
1W Performance:
-0.32%
1M Performance:
-32.76%
6M Performance:
-69.40%
1Y Performance:
-82.73%
1-Day Range:
$3.11
$3.39
1-Week Range:
$2.97
$3.46
52-Week Range:
$2.655
$20.40
23 Andme Holding Co Stock (ME) Company Profile
Name
23 Andme Holding Co
Sector
Industry
Phone
(650) 938-6300
Address
223 N. MATHILDA AVE., SUNNYVALE
Compare ME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ME
23 Andme Holding Co
|
3.14 | 82.53M | 247.99M | -521.97M | -194.28M | -0.72 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
23 Andme Holding Co Stock (ME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-22 | Initiated | Berenberg | Buy |
| Sep-22-22 | Initiated | Cowen | Outperform |
| Nov-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Initiated | Credit Suisse | Outperform |
| Jul-12-21 | Initiated | Citigroup | Buy |
23 Andme Holding Co Stock (ME) Latest News
23andMe’s stock falls after company says there’s substantial doubt it can stay in business - MSN
23andMe shares dip as Q2 loss widens despite revenue beat By Investing.com - Investing.com Nigeria
Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential? - Insider Monkey
Struggling 23andMe Is Exploring Splitting the DNA Company in Two - MSN
23andMe inks research deal with Mirador Therapeutics By Investing.com - Investing.com Canada
23andMe to slash 40% of its workforce, end therapeutics program to cut costs - MSN
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation - The Manila Times
23andMe inks research deal with Mirador Therapeutics - Investing.com India
23andMe and Mirador Therapeutics Enter Into Strategic - GlobeNewswire
23andMe Partners with Mirador in Major Drug Development Collaboration | ME Stock News - StockTitan
Earnings call: 23andMe announces restructuring and focus shift By Investing.com - Investing.com Australia
Earnings call: 23andMe announces restructuring and focus shift - Investing.com
23andMe Holding Co. (NASDAQ:ME) Q2 2025 Earnings Call Transcript - Insider Monkey
23andMe Reports Improved Financial Metrics Amid Revenue Decline - TipRanks
23Andme Holding Co earnings missed by $2.16, revenue topped estimates - Investing.com Canada
23andMe cuts 40% of its workforce - Fox Business
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs - Yahoo Finance
23andMe’s stock turns lower after company posts its latest quarterly loss - MSN
23andMe cuts 40% of its workforce, discontinues all therapy programs - Reuters
23andMe to Explore Strategic Alternatives - Marketscreener.com
23andMe Holding Co Reports Q2 FY25 Revenue of $44 Million, Missi - GuruFocus.com
23andMe Holding Co. (ME) Misses Q2 EPS by 216c - StreetInsider.com
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results - GlobeNewswire
23andMe Holding Co. Announces Reduce Overall Headcount - Marketscreener.com
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future - The Manila Times
23andMe Announces Business Restructuring to Streamline - GlobeNewswire
23andMe Cuts 40% of Workforce, Exits Therapeutics in Major Cost-Saving Overhaul | ME Stock News - StockTitan
Earnings Outlook For 23andMe Holding - Benzinga
Federal law could prevent your 23andMe data deletion, but you should still try - Android Police
CORRECTION23andMe to Report Q2 FY2025 Financial Results - The Manila Times
23andMe Revises Q2 FY2025 Earnings Release Time to Pre-Market on Nov 12 | ME Stock News - StockTitan
23andMe to Report Q2 FY2025 Financial Results - The Manila Times
23andMe Sets Q2 FY2025 Earnings Call for November 12: What Investors Need to Know | ME Stock News - StockTitan
Vanguard Group's Strategic Acquisition of 23andMe Shares - GuruFocus.com
DNA-testing site 23andMe fights for survival - BBC.com
23andMe turns to CFOs to fill director roles after mass board exit - Yahoo Finance
23andMe regains Nasdaq compliance, avoids delisting By Investing.com - Investing.com Australia
23andMe regains Nasdaq compliance, avoids delisting - Investing.com
23andMe Regains Nasdaq Compliance and Ensures Listing - TipRanks
23andMe Regains Compliance With Nasdaq Listing Requirements - The Manila Times
23andMe Stock Price Prediction: 2024, 2025, 2030 - Benzinga
23andMe Holding Expands Board with New Appointments - TipRanks
23andMe expands board with three new directors - Investing.com
23andMe Appoints Three New Independent Directors to Board - The Manila Times
23andMe expands board with three new directors By Investing.com - Investing.com UK
23 Andme Holding Co Stock (ME) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):